See the DrugPatentWatch profile for fondaparinux
Fondaparinux is a synthetic, selective indirect inhibitor of factor Xa [1]. It is a low molecular weight heparin analogue and is administered via subcutaneous injection [2]. The drug works by binding to antithrombin III, which then inactivates factor Xa and, to a lesser extent, thrombin [1].
What is fondaparinux used for?
Fondaparinux is prescribed to prevent venous thromboembolism (VTE) in patients undergoing hip fracture surgery or hip/knee replacement surgery [2]. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) [2].
How does fondaparinux differ from heparin?
While both fondaparinux and unfractionated heparin (UFH) are anticoagulants that work with antithrombin III, fondaparinux is a synthetic pentasaccharide that selectively inhibits factor Xa, whereas UFH inhibits both factor Xa and thrombin [1][3]. This selective action is thought to contribute to a potentially lower risk of heparin-induced thrombocytopenia (HIT) with fondaparinux compared to UFH [1].
When does fondaparinux's patent expire?
The patent landscape for fondaparinux is complex, with various patents covering the drug substance, formulations, and methods of use. Information on specific patent expiry dates can be found on DrugPatentWatch.com [4].
Can generic versions of fondaparinux be made?
The development of generic versions of fondaparinux is dependent on the expiry of relevant patents and regulatory approvals [4]. Companies often seek to develop biosimilar or generic alternatives once patent protection lapses.